Clinical applications of new aromatase inhibitorsEVANS, T. R. J.Critical reviews in oncology/hematology. 1994, Vol 16, Num 2, pp 129-143, issn 1040-8428Article

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I databaseCASSIER, P. A; POLIVKA, V; VOEST, E. E et al.Annals of oncology. 2014, Vol 25, Num 6, pp 1222-1228, issn 0923-7534, 7 p.Article

A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumorsSALAZAR, R; JONES, R. J; IGLESIAS DIOS, J. L et al.Cancer chemotherapy and pharmacology. 2012, Vol 70, Num 5, pp 673-681, issn 0344-5704, 9 p.Article

A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinomaEATOCK, M. M; ANTHONY, D. A; EI-ABASSI, M et al.British journal of cancer. 2000, Vol 82, Num 12, pp 1925-1931, issn 0007-0920Article

Bile duct stents : Is there an increased rate of complications in patients receiving chemotherapy ?LOFTS, F. J; EVANS, T. R. J; MANSI, J. L et al.European journal of cancer (1990). 1997, Vol 33, Num 2, pp 209-213, issn 0959-8049Article

A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancerEVANS, T. R. J; LOFTS, F. J; MANSI, J. L et al.British journal of cancer. 1996, Vol 73, Num 10, pp 1260-1264, issn 0007-0920Article

Protacted oral etoposide in epithelial ovarian cancer : a phase II study in patients with relapsed or platinum-resistant diseaseSEYMOUR, M. T; MANSI, J. L; GALLAGHER, C. J et al.British journal of cancer. 1994, Vol 69, Num 1, pp 191-195, issn 0007-0920Article

Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumorsDIAZ-RUBIO, E; EVANS, T. R. J; TABERNERO, J et al.Annals of oncology. 2002, Vol 13, Num 4, pp 558-565, issn 0923-7534Article

A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinomaMACKAY, H. J; MCINNES, A; EVANS, T. R. J et al.Annals of oncology. 2001, Vol 12, Num 10, pp 1407-1410, issn 0923-7534Article

Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharideDE BONO, J. S; DALGLEISH, A. G; CARMICHAEL, J et al.Clinical cancer research. 2000, Vol 6, Num 2, pp 397-405, issn 1078-0432Article

Trousseau's syndrome in association with ovarian carcinomaEVANS, T. R. J; MANSI, J. L; BEVAN, D. H et al.Cancer. 1996, Vol 77, Num 12, pp 2544-2549, issn 0008-543XArticle

Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinomaEVANS, T. R. J; ROWLANDS, M. G; LAW, M et al.British journal of cancer. 1994, Vol 69, Num 3, pp 555-561, issn 0007-0920Article

The biological evaluation of novel antioestrogens for the treatment of breast cancerCHANDER, S. K; SAHOTA, S. S; EVANS, T. R. J et al.Critical reviews in oncology/hematology. 1993, Vol 15, Num 3, pp 243-269, issn 1040-8428Article

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumoursMACPHERSON, I. R; POONDRU, S; SIMON, G. R et al.European journal of cancer (1990). 2013, Vol 49, Num 4, pp 782-789, issn 0959-8049, 8 p.Article

Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics : Targeted Cancer Therapies: Current Status and Future DirectionsVENUGOPAL, B; EVANS, T. R. J.Current medicinal chemistry. 2011, Vol 18, Num 11, pp 1658-1671, issn 0929-8673, 14 p.Article

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)STEELE, N. L; PLUMB, J. A; VIDAL, L et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 6, pp 1273-1279, issn 0344-5704, 7 p.Article

Auto-immune neutropenia occurring in association with malignant melanomaWHITE, J. D; MACPHERSON, I. R. J; EVANS, T. R. J et al.Oncology reports. 2003, Vol 10, Num 1, pp 249-251, issn 1021-335X, 3 p.Article

A phase ii trial of the vitamin D analogue seocalcitol (EB1089) in patients with inoperable pancreatic cancerEVANS, T. R. J; COLSTON, K. W; LOFTS, F. J et al.British journal of cancer. 2002, Vol 86, Num 5, pp 680-685, issn 0007-0920Article

Inflammatory demyelinating polyneuropathy : A complication of immunotherapy in malignant melanomaANTHONEY, D. A; BONE, I; EVANS, T. R. J et al.Annals of oncology. 2000, Vol 11, Num 9, pp 1197-1200, issn 0923-7534Article

A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapyO'NEILL, V. J; EVANS, T. R. J; PRESTON, J et al.Acta oncologica (Stockholm). 1999, Vol 38, Num 8, pp 1103-1107, issn 0284-186XArticle

Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancerEVANS, T. R. J; ROWLANDS, M. G; SILVA, M. C et al.Journal of steroid biochemistry and molecular biology. 1993, Vol 44, Num 4-6, pp 583-587, issn 0960-0760Conference Paper

A double-blind study of the efficacy of metronidazole gel in the treatment of malodorous fungating tumoursBOWER, M; STEIN, R; EVANS, T. R. J et al.European journal of cancer (1990). 1992, Vol 28A, Num 4-5, pp 888-889, issn 0959-8049Article

Oestrone sulphatase activity in mammary tumours and the liver of N-nitrosomethylurea treated ratsEVANS, T. R. J; CHANDER, S. K; ROWLANDS, M. G et al.British journal of cancer. 1992, Vol 65, Num 1, pp 72-76, issn 0007-0920Article

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal womenEVANS, T. R. J; DI SALLE, E; ORNATI, G et al.Cancer research (Baltimore). 1992, Vol 52, Num 21, pp 5933-5939, issn 0008-5472Article

Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumoursLASSEN, U; MILLER, W. H; BROWN, K et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 2, pp 543-549, issn 0344-5704, 7 p.Article